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1. Introduction
Dynamic cardiomyoplasty (DCMP) aims at improving cardiac function in cases of severe heart
failure by wrapping the latissimus dorsi (LD) muscle, (usually left LD) around the ventricles
and stimulating it electrically, synchronously to the ventricular function (Figure 1, Figure 2).
It is a surgical treatment option mostly for pharmacologically untreatable heart failure. The
first successful clinical application was performed in 1985 (Broussais Hospital, Paris, [1]). Since
then, more than 1.000 surgeries have been performed worldwide [2]. The clinical results of the
DCMP however did not live up to the expectations due to the loss of muscle strength [3][4]
and muscle damage [5][6].
In DCMP, a special kind of tissue engineering is applied using an electric stimulation on
autologous skeletal muscles (electrical muscular tissue engineering). The fiber type changes
from the fatiguing type IIa to the fatigue resistant type I [7], [8]. Type IIx fibers disappear. The
gene expression for myosin heavy chains IIa (MHCII) is changed into heavy chains I (MHCI)
[3]. Intramuscular collaterals are opened [9], [10] and enhanced and capillary density is
increased [11].
A critical analysis of more than 20 years and more than 1.000 clinical cases should demonstrate
it’s clinical impact [1], [2], [4–6], [12–145]. Clinical efficacy concerning survival, clinical
outcome indicated by NYHA- class, ejection fraction of the left heart ventricle (EF) was
evaluated by the use of more than 100 relevant reports. A comparison of the DCMP therapy
© 2013 Guldner et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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to other treatment options for end-stage heart failure is performed in this report. And last but
not least new experimental insights concerning the DCMP procedure should be demonstrated.
This experience from clinical application over more than 20 years and new experimental data
about dynamic cardiomyoplasty procedures should become compared and discussed. From
these insights, conclusions should be drawn to improve clinically results from DCMP which
are needed urgently for a more effective treatment of pharmacologically non-treatable heart
failure.
Figure 2. When latissimus dorsi muscle (LDM) has been transferred intra-thoracally it is wrapped around the heart
and stimulated electrically by a myostimulator via two muscular electrodes near the branches of the thoraco-dorsal
nerve. Stimulation bursts are synchronized with the heart action via additional epicardial sensing electrodes.
Figure 1. Latissimus dorsi muscle (LDM) is dissected free from the left thoracic wall before placing it into the thoracic
cavity via a window of the thoracic wall after a partial resection of the second rib. Artery, vein and nervus thoraco-
dorsalis remain untouched. LDM’s tendon is cut (arrow) before it’s re-fixation to the thoracic wall. Two stimulation
electrodes are placed wavelike around the branches of nervus thoracodorsalis at a distance of 6 cm.
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2. Clinical efficacy of DCMP
2.1. Survival
An analysis of survival curves of different investigators for DCMP-procedures shown in figure
3 may give insights in factors determining the best survival rate.
2.1.1. Survival rate and NYHA — Class
Observing and comparing the survival curves in figure 3 demonstrates, that a pre-operative
NYHA class III has a better long term survival than NYHA class IV. In the upper half of the
diagram with the higher survival, NYHA III is predominantly present while in the lower half
mostly appears NYHA IV.
Figure 3. Survival rates of patients with a DCMP published by different authors (a) Rigatelle et al, 2002 (ITDDC = Ita‐
lien Demand Dynamic Cardiomyoplasty) [118] (b) Chachques et al. 1997 [37] (c) Benicio et al. 2003, [20] (d) Bocchi et
al. 1994, [25] (e) Bocchi et al. 1996 [23]
To demonstrate the influence of the pre-operative NYHA class, results of the "French DCMP
Experience" from the year 1997 are selected from figure 3 and documented in figure 4
separately. The survival rate of class NYHA III patients at 5 years after DCMP was 68%
compared to NYHA IV with 23 % (Chachques JC, 1997) [37]. Another group reports (figure 3
(d)) about no survivor of pre-operative NYHA IV patients 3 years after the DCMP procedure
[25].
2.1.2. Survival rate and stimulation pattern
A re-evaluation of long-term outcomes of dynamic cardiomyoplasties from the Sao Paulo
Group Brazil [20] in 43 patients with dilated cardiomyopathies showed impressive results
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using different stimulation modes by synchronizing the electrical stimulation of the muscle
wrap to the heart in 1:1 and 1:2 mode (stimulations bursts per heart beat). In 1:2 mode after 10
years of DCMP, there is a survival of about 40 % while in 1:1 there is no survivor. A muscle
damage as shown in the histology (figure 11, chapter 2.5, [5]) using also a 1:1 stimulation
pattern may be the reason of this insufficient result.
Figure 5. Survival rate of DCMP procedures 10 years after different synchronization modes with the heart contractions.
1:2 synchronization results in a 40 % survival, while in a 1:1 mode there was no survivor. (a) Benicio et al. 2003, [20]
Figure 4. Kaplan-Meier statistics of the event-free survival after dynamic cardiomyoplasty according to pre-operative
New York Heart Association functional class (upper curve NYHA III, lower curve NYHA IV) (a) Chachques, 1997, [37]
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The highest survival rate, upper curve in figure 3 (a), has been reported by Rigatelli et. al 2003
[118]. They applied the lowest mean pulse frequency of all investigators and used a day and
night regime with a myostimulator on at day and off at night.
2.2. NYHA — Class
In order to determine the best course of therapy, physicians often assess the stage of heart
failure according to the New York Heart Association (NYHA) functional classification system.
This system relates symptoms to everyday activities and the patient's quality of life.
• Class I (Mild): No limitation of physical activity. Ordinary physical activity does not cause
undue fatigue, palpitation, or dyspnea (shortness of breath).
• Class II (Mild): Slight limitation of physical activity. Comfortable at rest, but ordinary
physical activity results in fatigue, palpitation or dyspnea
• Class III (Moderate): Marked limitation of physical activity. Comfortable at rest, but less
than ordinary activity causes fatigue, palpitation, or dyspnea
• Class IV (Severe): Unable to carry out any physical activity without discomfort. Symptoms
of cardiac insufficiency at rest, if any physical activity is undertaken.
In 101 from 139 publications about clinical DCMP authors report about the efficacy of DCMP
on the clinical severity in heart failure using the classification of the New York Heart Associ‐
ation (NYHA). The DCMP outcome is reported between 1989 and 2009.
In figure 6 the higher bars in all cases represent the pre-operative NYHA-class and the lower
bars show the post-operative results. In summary there is a significant improvement from
NYHA 3.26 ± 0.63 to 1.69 ± 0.34 (p<0.05, figure 7).
Figure 6. Clinical outcome between 1989 and 2009 evaluating 101 reports from literature shows an improvement of
NYHA from pre-operatively 3.26 to post-operatively 1.69 (p< 0.05).
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p < 0.05
Figure 7. Mean values of the pre-operative (left) and post-operative (right) NYHA-classes (p< 0.05).
2.3. Hospitalization rate
Evaluating data from 264 patients of 7 publications [31], [35], [40], [96], [118], [136], [138], the
pre-operative hospitalization rate was 2.79 ± 0.83 days/year. The post-operative hospitaliza‐
tionrate of DCMP patients was significantly decreased with 0.48 ± 0.23 days/year (Figure 8).
p < 0.05 
0.48 ± 0.23 d/y.
2.79 ± 0.83 d/y.
Figure 8. Mean values of the pre-operative (left) and post-operative (right) hospitalization (p< 0.05).
Regenerative Medicine and Tissue Engineering800
2.4. Ejection Fraction (EF)
According to the clinical improvement documented by the NYHA-decline in figure 6, there is
an increase of the ejection fraction (EF) of the left heart ventricle from 21.8 ± 4.5 to 28.9 ± 5.9
(p< 0.05). Figure 9 demonstrates an overview of the ejection fraction (EF) of 89 DCMP relevant
reports.
p < 0.05
Figure 9. Ejection fraction (EF) after DCMP improved from 21.9 to 28.9%
2.5. PV-loop evaluation
The conductance catheter method visualizes an impressive documentation of DCMP' s clinical
efficacy. It is performed by heart catheterization where a conductance catheter is placed along
the longitudinal axis of the left heart ventricle (LV). It enables a real time volumetry of the
stroke volume of the LV by recording the changes of intra-ventricular blood conductivity
caused by a volume reduction (stroke volume). A simultaneous measurement of the LV's
pressure allows generating pressure-volume loops in real time. The area surrounded by the
loop represents the stroke work of the left heart ventricle. Thus the influence of an activated
DCMP on the hemodynamic of the LV can be demonstrated as shown in figure 10(n=9 patients).
A stimulated DCMP enhances the stroke work of the left ventricle.
In three patients A, B and C (Figure 11, [74]), left ventricular pressure-volume loops and
relations performed by the conductance method are recorded before the cardiomyoplasty
procedure and 1 year after surgery. As demonstrated by example in the baseline panel for
patient A, multiple pressure- volume loops are used to measure end-systolic pressure-volume
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relation (ESPVR) and diastolic pressure-volume relation (DPVR), defining the active and
passive limits of cardiac performance, respectively.
Summarizing the results of Kass et al., the most important finding is a leftward shift of the PV-
loop, indicating a volume reduction of the dilated, failing heart. This reverse remodelling
improves left ventricular performance.
2.6. Histology
Dynamic cardiomyoplasty patients had an initial clinical improvement followed by a decrease
in cardiac failure indices mostly in a 1:1 stimulation mode [20]. A histopathological study of
the skeletal muscle was undertaken by Gutierrezz et al. 2001 [5] to explain this. Latissimus
dorsi fragments from 15 patients submitted to dynamic cardiomyoplasty in a 1:1 conditioning
were analysed by light microscopy. The interval between surgery and obtaining the specimens
(13 from necropsies, two from heart transplants) ranged from 37 days to 6 years. Nuclear
Figure 10. Pressure-volume-loops of 9 patients. The dotted lines represent non-supported and the solid lines show
DCMP-supported heart cycles. Vlv expresses the volume of the left ventricle and Plv represents left ventricular pres‐
sure. (Schreuder et al.1995 [130])
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clumps and internalization, the presence of round fibres, inflammation, and fibrosis were
analysed semi-quantitatively; the thickness of muscle fibres and the percentage of tissue fat
were measured by image analysis. The quantitative data were also compared, in 12 cases, with
gender- and age-matched necropsy controls. The mean thickness of muscle fibres in cases and
controls was 27.21 ± 5.33 and 40.84 ± 9.42 μ, respectively (p=0.001). The percentage of tissue fat
in cases and controls was 12.04 ± 12.66% and 0.93 ± 0.91%, respectively (p=0.008). Accordingly,
a negative correlation was found between the duration of graft usage and the mean diameter
of fibers, characterizing muscle atrophy (R=-0.66, p=0.01). The longer the post-surgical period,
the more intense the degenerative lesions. This study shows that skeletal muscle used in
human dynamic cardiomyoplasty may atrophy and be replaced by fat when stimulation is
synchronized to every cardiac beat [20]. These findings could play a role in explaining the long-
term results in DCMP procedures as shown in Fig.5 chapter 1.2.1 with no survivors after 10
years of an electrical stimulation in a 1:1 mode.
Figure 11. Effect of cardiomyoplasty on cardiac function by pressure volume relations one year after the operative
DCMP procedure [74].
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Figure 12. Histology of severe muscle damage is demonstrated using an 1:1 over stimulation. (Gutierrez et al. J Pathol
2001; 194: 116-121) [5]
3. DCMP in comparison to other clinical treatment options for patients with
end-stage heart failure
3.1. Medical treatment
The only prospective randomized study comparing DCMP with the medical treatment is C-
SMART (Cardiomyoplasty Skeletal Muscle Assist Randomized Trial, [145]). All 103 patients
suffered from cardiac failure of NYHA III. C-SMART showed that after 6 months quality of
life and sub-maximal physical performance was increased significantly. The main limitation
of this study was the short observation time of 6 months. This American study was finished
due to the inability to recruit further patients. After these 6 months survival rate did not differ
significantly. Due to the knowledge that the DCMP is effective after a longer post-operative
period interval we have to rely on retrospective studies only including DCMP patients [20],
[118] and medical treated over more than 4 years ([23], [146], [147], [148]). The most favourable
medical therapy in NYHA III was comparable to the best results of DCMP patients in the same
NYHA class. Summarizing the results of these studies comparing DCMP with medical
treatment, following statements can be made:
1. As long as medical treatment is effective, it should be continued.
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2. If medical therapy in NYHA III gets insufficient and patients are going to move towards
NYHA IV, a DCMP is indicated. The poor results of a medical treatment applied in NYHA
IV is visible in the lowermost curve of figure 13 (f).
3. Patients having been in NYHA IV and recovered to NYHA III are candidates for a DCMP
as well.
4. When a DCMP is stimulated by a stimulation pattern with less stimulation pulses, the
surgical treatment might become superior to a medical treatment in future (compare
topmost curve of figure 13 (a) stimulated with less pulses and using a day and night
regime, having no stimulation at night.)
Figure 13. Clinical efficacy of the DCMP (NYHA III/IV, 1:2) in comparison to medical treatment options. (a) Rigatelli,
2002, [118] (b) Benicio, 2003, [20] (c) COMET, Poole-Wilson, 2003 [146] (d) CARE-HF, Cleland, 2005 [148] (e) Bocchi,
1996, [23] (f) REMATCH, Rose, 2001, [147]
3.2. Cardiac resynchronization therapy (CRT)
Comparing survival rate of DCMP and cardiac resynchronization therapy (CARE-HF, CRT-
group, [148]), some authors found superior and others equivalent results. The DCMP proce‐
dure is more invasive and expensive than a CRT. But indication for a CRT is a heart failure in
combination with a desynchronization of the left and right ventricle (left or right bundle branch
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block). Additionally CRT is not effective in one third of these patients. Those are candidates
for a DCMP.
Figure 14. Efficacy of the DCMP in comparison to the cardiac resynchronisation therapy (CRT) in patients with bundle
branch blocks. (a) Rigatelli, 2002 [118], (b) Chachques 1997, [37], (c) Benicio, 2003 [20], (d) CARE-HF Cleland, 2005
[148]
3.3. Heart transplantation
Comparing clinical results from the DCMP to those from the heart transplantation (HTX), their
survival rates are comparable (figure 15, (a,b,c) vs. (d) [ISHLT, Heart Transplantation, Annual
Report 2011 [149])). Objection however is, HTX is mainly suitable to NYHA class IV and DCMP
to NYHA III. Taking in account the tremendous lack of donor hearts, it is to consider to apply
the DCMP as early as possible in the non-effective medical treatment of NYHA III patients, to
avoid a manifest stadium NYHA IV. Furthermore patients with a DCMP have no contraindi‐
cation for HTX procedure. That is why DCMP can be regarded as a bridge to transplant [2]
over years. In conclusion DCMP can contribute to a therapy of end-stage heart failure post‐
poning HTX for years.
3.4. Left heart assist devices
Figure 16 indicates that a therapy by left heart assist devices (LVADs) is inferior to HTX, but
due to the lack of donor hearts it is often the only treatment option in severe heart failure. A
DCMP in NYHA III however may postpone a LVAD or HTX procedure. A comparison of
DCMP and LVADs [150] count similar limitations like mentioned in HTX above, concerning
the comparison of groups with different NYHA classes.
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Figure 16. Efficacy of DCMP in comparison to mechanical assist devices (HeartMate II) and heart transplantation
(HTX). (a) Rigatelli, 2002, [118], (b) Chachques, 1997 [37], (c) Benicio, 2003 [20], (d) ISHLT, 2011, [149] (e) Park, 2012,
[150]
3.5. Stem cell therapy
The stem cell therapy of the human myocardium with mesenchymal stem cells (MSCs) has
been evaluated in several clinical studies [151], [152]. The MSCs were applied intracoronar‐
illy  after  myocardial  infarction,  and  intra-myocardially  solely  and  in  combination  with
aorto-  coronary bypass-surgery [153].  Thereby the ejection fraction (EF)  of  the left  heart
ventricle was seldom enhanced by more than 5% in the long time. The therapeutic effect
never lasted longer than 6 to 9 months which was due to the disappearance of the MSCs
Figure 15. Clinical efficacy of a DCMP treatment in comparison to heart transplantation (HTX). (a) Rigatelli,2002, [118]
(b) Chachques, 1997, [37] (c) Benicio, 2003 [20] (d) ISHLT, 2011, [149]
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from the myocardium within several months. Thereafter MSC's were found predominant‐
ly  in  liver  and  spleen.  Thus  DCMP  treatment  might  be  superior  to  a  MSC'  s  therapy,
however there are not enough comparative clinical data yet. A combination of both seems
favourable.  An  additive  therapeutic  effect  specially  with  a  stem  cell  transforming  into
cardiomyocytes  and  a  permanent  homing  within  the  myocardium  might  enhance  this
therapy (Guldner et al. 2006, [154], 2009, [155]).
4. Summarizing appraisal of the clinical efficacy from DCMP
Evaluating 139 papers from literature about clinical dynamic cardiomyoplasty, DCMP showed
to be effective accordingly to survival rate, NYHA class, hospitalization rate and ejection
fraction of the hemodynamic from the left heart ventricle. Survival rate was clinically relevant
higher in NYHA class III than in NYHA IV (Figure 4, [37]) and additionally more patients
survived synchronized in 1:2 mode than in 1:1 pacing (Fig.5, [20]). Quality of life showed to
be enhanced by a decreased NYHA of 1.57 (pre-operatively NYHA 3.26 ± 0.63 to post-
operatively NYHA 1.69 ± 0.34 [p<0.05]). The ejection fraction of the left heart ventricle was
increased from 21.9 ± 4.5 % to 28.9 ± 5.9% (p<0.05). A better clinical outcome is documented in
cases with a reduced electrical stimulation [4], [33], [34], [117–125] accompanied with a day
and night regime. A higher stimulation frequency might result in a muscle damage [5].
Dynamic cardiomyoplasty in comparison to other treatment options for end-stage heart failure
like heart transplantation, resynchronization therapy, mechanical left ventricular assist
devices and stem cell therapy has a clearly defined therapeutic indication. These are patients
with a non-pharmacologically treatable heart failure of the NYHA class III and the non-
responders of the resynchronization therapy (CRT). Due to poor therapeutic results, NYHA
IV class patients are not to be considered for a DCMP.
5. Rational of pre-stimulation
Enhanced capillary density in skeletal muscle, induced by different stimulation patterns, has
been well investigated in small animals [156], [157] and only a few investigations are in big
animals [11]. But these experiments seldomly correlate capillary density with blood flow. Thus,
an evaluation of blood flow, and capillary density of a clinically feasible two weeks electrically
in-situ-conditioning in latissimus dorsi muscle (LDM) was investigated at rest and exercise in
human sized animals. In five adult female Boer goats (52±9 kg), the left LDM (group I) was
stimulated in-situ electrically over 14 days (10 Hz, 2-5V, 12h/day, 1h on-1h off). The right LDM
served as control (group II). After conditioning, the LDMs blood flow was measured at rest
and exercise ( electric muscle stimulation over 10 minutes) by an ultrasonic flow probe around
the A. thoracodorsalis. Muscle samples of different regions of LDM were harvested to evaluate
the capillary to fiber ratio, mean diameter of the muscle fibers and their myosin heavy chain
composition (type I /II).
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*Figure 17. Operative situs in a goat during flow evaluation.The neuro-vascular bundle including the arteria thoraco-
dorsalis leading to the latissimus dorsi muscle is demonstrated (arrow). The flow probe (*) is situated around the arte‐
ria thoraco-dorsalis.
Blood Flow in LDM under Work and Rest
Work Work
Flow [ml/s] Flow [ml/s] 
Figure 18. Blood flow within the Arteria thoraco-dorsalis of a non pre-stimulated LDM in a goat in-situ (left) in com‐
parison to the same setting 14 days after electrically pre-stimulation of LDM in-situ (right) The pre-stimulated LDM
(right) showed a higher blood flow under work conditions during a 10 minutes burst stimulation (work).
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Figure 19. Change of blood flow [%] in arteria thoracodorsalis of non- (white spots)- and pre-stimulated (black spots)
LDM (p≤0.05*) under rest, exercise (stimulation) and recovery. The two weeks stimulated muscle (n=5) shows a signifi‐
cant higher blood flow under exercise and recovery (*).
In group I, the pre-stimulated muscle (black spotted curve) shows an increased mean blood
flow from 5.0±2.4 ml/min at rest to 30.2±2.7 ml/min under exercise. In group II, blood flow was
5.1±2.8 ml/min at rest and 19.9±0.9 ml/min under exercise. Therefore flow under exercise
increased to 51.8% (p ≤ 0.01).
5.1. Collaterals
Within latissimus dorsi muscle there exist two arterial territories. A proximal one supported
by the thoracodorsal artery and a distal territory supplied by perforating arteries deriving from
intercostal arteries. Mobilization of the latissimus dorsi muscle as a functional graft necessarily
involves division of perforating arteries that enter the distal portion of the muscle causing an
ischemic tissue with a loss in function.
Between the two arterial territories anastomotic connections are well described by Salmons
et.al 1998 [9]. In clinical applications, the existence of anastomotic connections offers the
prospect of maintaining flow to the distal part of the grafted muscle. Electrical stimulation
enhances blood flow through these anastomoses (Tang et al, 1998 [10]) demonstrated in a sheep
model that a pre-stimulation of LDM in situ over two weeks increases blood flow in the distal
part of LDM to a normal range while a reduction of flow by 50% was found in the untreated
muscle. Own experience with pre-stimulated LDM in situ in goats confirm these findings. Pre-
stimulated LDM's distal part looked well perfused after dissection but ischemic without pre-
stimulation. We conclude, electrical pre-stimulation of the latissimus dorsi muscle in situ
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reduces the acute distal ischemia of LDM caused by surgical manipulations, and promotes
subsequent recovery of blood flow.
In conclusion, applying pre-stimulation in-situ before a DCMP procedure might result in a
relevant functional advantage and might prevent muscle damage in the distal muscle tissue
of the LDM.
5.2. Capillary density
Experimental own data from big animal experiments in Fig.20 and Fig.21 and experimental
papers of others dealing with muscle powered cardiac assist show that a pre-stimulation of
the LDM in-situ enhances LDM's capillarization.
Capillaries
in Non Pre-Stimulated and Pre-Stimulated LDM
Mag: 100x Capillary to muscle fiber ratio: + 54,3%
(n=6)
Figure 20. Histologic visualization of cross-section areas from LDMs muscle fibers surrounded by capillaries (black
dots), in the stimulated muscle (right) exists a higher number of capillaries than in the non-stimulated LDM (left).
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C/F ratio in muscular tissue in five boore goats of non (white block)- and pre-stimulated (black 
block) LDM ( p≤0.05*; p≤0.01**,n.s. = not significant;).
Figure 21. 14 days of electrical stimulation increased the capillary to fiber ratio in goat's LDM (n=5) to 38% (black
columns) in comparison to the non-stimulated contra- lateral LDM control (white columns). (* p < 0.05; ** p < 0.01;
n.s. not significant)
Ischemic damage in the latissimus dorsi muscle may limit the success of cardiomyoplasty.
Electrical pre-stimulation of the muscle in situ is known to enhance capillarization and
thoracodorsal perfusion to the distal latissimus dorsi muscle immediately after grafting. Use
of a pre-stimulated graft may therefore improve the outcome of skeletal muscle cardiac
assistance (Tang et. al,1998, [10])
6. Closed-Loop Controlled Stimulation (CLC-Stimulation)
Since the basic experimental investigations of Salmons [7] and Pette [3], [8] it was evident, that
the number of electrical pulses to a muscle fibre determines its fibre type. They showed that
it is possible to transform a fast twitching fatigable IIa muscle into a fatigue resistant type I
fibre muscle by increasing the number of pulses within a defined stimulation pattern. At the
first glance it seemed to be ideal to substitute a damaged non-fatigable heart muscle by a slow
twitching non-fatigable skeletal muscle. However, this dream was not to fulfil the expectations
of muscle powered cardiac assistance clinically due to a tremendous loss of power in type I
fibre muscles combined with a reduced contraction velocity. Nevertheless the DCMP showed
to be effective clinically in certain limits as shown before.
Experimental investigations of Lopez-Guajardo et al. 2001 [158] demonstrated that a mean
pulse reduction within certain limit results in a strong and non-fatigable muscle. But there was
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a limitation: the time of usage of this non-fatigable type II a muscle was restricted. Otherwise
the muscle transformation would continue into type I fibres with all the negative consequences
of power loss and a decreased contraction velocity. Therefore a controlled pulse management
is mandatory to keep non-fatigable type IIa muscle fibres. This restriction in pulses however,
goes along with a time-wise limited usage for a cardiac support. This fact has major implica‐
tions for a restricted usage in muscle powered cardiac assist with no blood contact like the
DCMP and even more in muscular blood pumps [159–161].
To fulfil these demands in electrically stimulated muscular cardiac support to maintain a non-
fatigable strong muscle with a preserved contraction velocity, myostimulators are mandatory
to enable a closed-loop controlled stimulation.
6.1. Technical basics for a closed-loop controlled muscle stimulation
In order to protect the assisting muscle, the new Microstim myostimulator will prevent chronic
overstimulation which results in an undesired muscle fiber transformation and degeneration.
The fiber transformation to type I would lead to a subsequently reduced contraction velocity
and muscle force accompanied by a reduced cardiac support with structural and functional
muscle damage.
A closed-loop is designed to limit the amount of applied stimulation pulses below a certain
maximum value of mean stimulation frequency over a given period, e.g. 0.7 Hz mean stimu‐
lation frequency within 24h. This closed-loop is used to maintain the fast and powerful
twitching type IIa muscle fibres needed for a sufficient muscle powered cardiac assistance.
Mean
heart
rate
X
Mean  
pulse 
rate
Mean
stimulation
rate
=
Patient gets 
warning
Patient 
takes rest
Reduction
of heart rate
Feedback 1
Reduction of 
pulse delivery
per time
Feedback 2
Count of delivered stimulation pulses over time 
with comparison to target value
6 76 7656677
Figure 22. Closed-loop control to prevent muscular overstimulation. In feedback path 1, the patient receives a warn‐
ing message via RF from the implanted myostimulator to a wearable patient monitor. Feedback path 2 intrinsically
reduces the pulse delivery in accordance to programmed parameters.
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In two groups of goats, skeletal muscle ventricles (SMVs) were shaped intra-thoracically [159],
[160]. In group A (n=6) goat’s LDM was not pre-stimulated and SMVs contracted by bursts of
a mean pulse frequency of 5 Hz. This mean frequency of approximately 5 Hz has been used
clinically in more than 1000 cases up to now, resulting in severe muscle damage as shown
above in chapter 2.2. Group B, LDM with pre-stimulation over 14 days as shown above and
with a controlled stimulation with a mean pulse frequency not exceeding 1Hz mean pulse
frequency showed a preserved muscle tissue (figure 23, right). This new stimulation regime
in group B became feasible by the newly available myostimulator with an integrated feature
for muscle protection (MyoSen ® Myostim GmbH, Wismar, Germany).
Musculus latissimus dorsi after 6 months of electrical stimulation
Group A: 5 Hz Group B: 1 Hz
Figure 23. Histology of LDM 6 months after electrical stimulation with 5Hz and without pre-stimulation resulting in
severe muscle damage (left) and LDM with pre-stimulation over 14 days and closed-loop controlled stimulation with a
mean pulse frequency of 1Hz and preserved muscle tissue.
7. DCMP vs. CLC- DCMP — Clinical implications
This special kind of "electrical tissue engineering" of the LDM in situ 14 days before wrapping
the LDM around the heart and a controlled electrical stimulation pattern with a reduced mean
pulse frequency minor 1Hz should significantly increase the clinical efficacy of DCMP which
has been described above. The new pre-stimulated, controlled cardiomyoplasty (CLC-CMP)
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or its combination with intra-myocardial injections of adult stem cells (Stem Cell Cardiomyo‐
pexy) might open new fields in the therapy of pharmacologically untreatable heart failure.
Comparing DCMP vs. CLC- DCMP, the expected efficacy of CLC- DCMP, well based on facts
as shown above, should become an effective and reliable treatment option for end-stage heart
failure with much better therapeutic results as shown in clinical DCMP up to now. A combi‐
nation with an intramyocardial stem cell therapy is desirable [154], [155].
Figure 24. Pre-stimulated and such hypercapillarized muscle, wrapped around the heart for indirect revascularization
and girdling using a stimulation with a reduced number of pulses as a controlled cardiomyoplasty (CLC-DCMP).
8. Conclusion
DCMP has been effective clinically but did not fulfil the therapeutic expectations. Additional
treatment processes like pre-stimulation in situ and CLC-DCMP-pacing may increase clinical
efficacy for patients with a refractory medical treatment in NYHA III in future.
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